Diabetes Care Quarterly (THB) at Dr. Essa Lab

Diabetes Care Quarterly (THB) at Dr. Essa Lab

Diabetes mellitus is a chronic, progressive metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Uncontrolled diabetes leads to severe microvascular complications, including diabetic nephropathy, retinopathy, and neuropathy, as well as macrovascular diseases such as coronary artery disease, stroke, and peripheral arterial disease. To mitigate these risks, systematic and structured monitoring is essential. The Diabetes Care Quarterly (THB) at Dr. Essa Lab is a premier, comprehensive diagnostic panel designed specifically for the ongoing, three-monthly assessment of diabetic patients. This specialized panel provides clinicians and patients with a detailed metabolic roadmap, facilitating timely therapeutic adjustments and early detection of target organ damage.

The three-month interval of this panel is clinically strategic. It directly corresponds to the average lifespan of human erythrocytes, which is approximately 120 days. By measuring Glycated Hemoglobin (HbA1c), the Diabetes Care Quarterly (THB) panel offers an accurate, weighted average of a patient’s blood glucose levels over the preceding 8 to 12 weeks. Unlike daily self-monitoring of blood glucose, which provides isolated snapshots, HbA1c serves as the gold standard for assessing long-term glycemic control. Dr. Essa Laboratory & Diagnostic Centre, established in 1987 in Karachi, Pakistan, utilizes state-of-the-art automated platforms to perform this panel, ensuring that patients receive highly precise, reproducible, and clinically actionable results to guide their diabetes management journey.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the biochemical parameters evaluated in the Diabetes Care Quarterly (THB) panel, patients must strictly adhere to the following pre-analytical preparation guidelines:

• Fasting Requirements: Patients are required to fast for a minimum of 8 to 12 hours prior to sample collection. During this fasting period, no food, caloric beverages, juices, tea, or coffee should be consumed.
• Hydration: Adequate hydration is highly recommended. Patients should drink plenty of plain water during the fasting period, as dehydration can artificially elevate serum creatinine and hematocrit levels.
• Medication Management: Patients should consult their referring physician regarding their morning diabetes medications. Typically, oral hypoglycemic agents or insulin should not be administered immediately before the blood draw to prevent acute hypoglycemia, but routine non-diabetic medications can be taken with water.
• Avoid Alcohol and Strenuous Exercise: Alcohol consumption and vigorous physical activity should be avoided for at least 24 hours before the test, as they can alter glucose metabolism and renal clearance markers.
• Timing of the Test: It is highly recommended to schedule the sample collection in the early morning hours to align with standard reference ranges for fasting parameters.

During the Procedure

The Diabetes Care Quarterly (THB) panel requires both blood and urine specimens. The collection process is conducted under strict aseptic conditions by highly trained phlebotomists at Dr. Essa Lab:

• Venipuncture Process: The patient is comfortably seated. The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa. The area is thoroughly sanitized using a 70% isopropyl alcohol swab in a unidirectional or outward spiral motion.
• Sample Collection: A sterile, single-use vacuum needle system is used to draw blood. Multiple tubes are filled in a specific order of draw to prevent cross-contamination of additives. This includes a gray-top tube for precise plasma glucose preservation, a lavender-top tube for HbA1c analysis, and a gold or red-top tube for renal function testing.
• Urine Specimen Collection: The patient is provided with a sterile, leak-proof container and instructed on how to collect a clean-catch midstream urine sample. This involves cleansing the urethral meatus, discarding the initial stream of urine, and collecting the middle portion to minimize contamination from external skin flora.
• Post-Collection Care: Gentle pressure is applied to the venipuncture site with a sterile cotton ball, followed by the application of an adhesive bandage. The patient is advised to keep the bandage on for at least one hour and avoid heavy lifting with that arm. The entire procedure is virtually painless, safe, and completed within 10 to 15 minutes.

When is a Diabetes Care Quarterly (THB) Performed?

Monitoring Glycemic Control in Type 2 Diabetes

Physicians routinely request the Diabetes Care Quarterly (THB) panel for patients diagnosed with Type 2 Diabetes Mellitus to evaluate the long-term efficacy of their therapeutic regimen. Because Type 2 diabetes is characterized by progressive insulin resistance and beta-cell dysfunction, treatment plans—including lifestyle modifications, oral hypoglycemic agents, and GLP-1 receptor agonists—require regular optimization. This panel provides the essential HbA1c and glycemic data needed to determine if the patient is meeting their target glycemic goals, thereby preventing chronic microvascular complications.

Evaluating Insulin Therapy in Type 1 Diabetes

For individuals with Type 1 Diabetes Mellitus, who rely entirely on exogenous insulin, maintaining glycemic stability is an ongoing challenge. These patients are highly susceptible to rapid glycemic excursions, including severe hypoglycemia and diabetic ketoacidosis. The quarterly panel assists endocrinologists in assessing the overall stability of the patient’s basal-bolus or insulin pump regimen. By analyzing the quarterly trends, clinicians can make precise adjustments to insulin-to-carbohydrate ratios and basal rates to minimize glycemic variability.

Early Detection of Diabetic Nephropathy

Diabetic nephropathy is a leading cause of end-stage renal disease globally. The Diabetes Care Quarterly (THB) panel includes critical renal biomarkers, such as Serum Creatinine, Estimated Glomerular Filtration Rate (eGFR), and Urine Microalbumin. Physicians order this panel quarterly to screen for early signs of glomerular damage. Detecting microalbuminuria—the excretion of small amounts of albumin in the urine—allows for early intervention with renal-protective medications, such as ACE inhibitors or ARBs, which can halt or reverse the progression of kidney damage.

Assessing Cardiovascular Risk Factors

Diabetes is a major independent risk factor for cardiovascular disease. Chronic hyperglycemia induces endothelial dysfunction, accelerating atherogenesis. By monitoring glycemic control and renal function simultaneously through this quarterly panel, healthcare providers can assess the patient’s overall metabolic health. Renal impairment, indicated by a declining eGFR or persistent microalbuminuria, is a strong independent predictor of cardiovascular events, prompting clinicians to initiate aggressive lipid-lowering and blood pressure therapies.

Managing Prediabetes and Preventing Progression

In patients diagnosed with prediabetes or impaired glucose tolerance, the transition to overt Type 2 diabetes is not inevitable. Physicians utilize the Diabetes Care Quarterly (THB) panel to closely monitor high-risk prediabetic individuals who are undergoing intensive lifestyle interventions or metformin therapy. Quarterly tracking of HbA1c and fasting glucose levels provides immediate feedback on the success of these preventive strategies, allowing for timely adjustments to halt the onset of clinical diabetes.

What Does a Diabetes Care Quarterly (THB) Detect?

The Diabetes Care Quarterly (THB) panel is highly sensitive and capable of detecting a wide range of physiological and pathological states related to glucose metabolism and renal health. Specifically, this panel assists in identifying:

• Optimal glycemic control (HbA1c less than 7.0% in diabetic patients).
• Suboptimal glycemic control (HbA1c between 7.0% and 8.0%).
• Poor glycemic control (HbA1c greater than 8.0%), indicating a high risk of vascular complications.
• Impaired fasting glucose (fasting plasma glucose between 100 and 125 mg/dL).
• Overt fasting hyperglycemia (fasting plasma glucose equal to or greater than 126 mg/dL).
• Acute hypoglycemia (blood glucose less than 70 mg/dL), which requires immediate clinical intervention.
• Normal renal function (eGFR greater than 90 mL/min/1.73m² with normal creatinine).
• Mildly decreased renal function (eGFR between 60 and 89 mL/min/1.73m²).
• Moderate renal impairment (eGFR between 30 and 59 mL/min/1.73m²), indicating Stage 3 Chronic Kidney Disease.
• Severe renal insufficiency (eGFR between 15 and 29 mL/min/1.73m²).
• End-stage renal disease (eGFR less than 15 mL/min/1.73m²).
• Microalbuminuria (urine albumin-to-creatinine ratio or microalbumin levels indicating early nephropathy).
• Macroalbuminuria (significant protein excretion, indicating advanced diabetic nephropathy).
• Glucosuria (presence of glucose in urine, indicating blood glucose levels exceeding the renal threshold).
• Ketonuria (presence of ketones in urine, a critical marker for diabetic ketoacidosis).
• Urinary tract infections (indicated by the presence of leucocytes, nitrites, or bacteria in the urine detail report).
• Dehydration or pre-renal azotemia (indicated by elevated serum creatinine with normal urine findings).
• Fluctuations in glycemic control due to medication non-adherence.
• Efficacy of newly initiated oral hypoglycemic agents or insulin therapy.
• Impaired glomerular filtration secondary to long-standing hypertension or diabetes.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, we understand that timely diagnostic insights are critical for effective clinical decision-making. Utilizing fully automated, high-throughput chemistry and immunoassay analyzers, we ensure that the components of the Diabetes Care Quarterly (THB) panel are processed with maximum efficiency and accuracy. The standard turnaround time for this comprehensive panel is within 12 to 24 hours from the time of sample collection.

Patients can conveniently access their diagnostic reports through multiple digital channels. Dr. Essa Lab offers an advanced online reporting portal on its official website, where patients can view, download, and print their reports using their unique lab ID and password. Additionally, reports can be accessed via the dedicated Dr. Essa Lab mobile application. For patients who prefer physical copies, reports can be collected from any of our numerous diagnostic centers and collection points strategically located across Karachi and other cities in Pakistan.

Diabetes Care Quarterly (THB) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HbA1c (Glycated Hemoglobin)	Non-diabetic: < 5.7%; Diabetic Target: < 7.0%	Prediabetes: 5.7% – 6.4%; Poor Control: > 8.0%
Fasting Blood Glucose	70 – 99 mg/dL	Impaired: 100 – 125 mg/dL; Diabetic: ≥ 126 mg/dL
Serum Creatinine	Male: 0.7 – 1.3 mg/dL; Female: 0.6 – 1.1 mg/dL	Elevated: > 1.3 mg/dL (indicating renal impairment)
eGFR (Estimated GFR)	≥ 90 mL/min/1.73m²	Decreased: < 60 mL/min/1.73m² (indicates kidney disease)
Urine Microalbumin	< 30 mg/g (or < 20 mg/L)	Microalbuminuria: 30 – 300 mg/g; Macroalbuminuria: > 300 mg/g
Urine Glucose	Negative	Positive (Glucosuria, indicating hyperglycemia)
Urine Ketones	Negative	Positive (Ketonuria, warning of diabetic ketoacidosis)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Diabetes Care Quarterly (THB)?

• Decades of Diagnostic Trust: Established in 1987, Dr. Essa Lab is one of Pakistan’s most trusted and recognized names in pathology and diagnostic imaging.
• ISO Certified Quality Standards: Our laboratories operate under strict ISO 9001 certification and participate in rigorous external quality assurance programs.
• Expert Clinical Oversight: Every diagnostic panel is supervised, analyzed, and signed off by highly qualified consultant pathologists and clinical chemists.
• Advanced Analytical Technology: We utilize state-of-the-art, fully automated chemistry and immunoassay platforms to ensure maximum precision and minimize human error.
• Convenient Home Sample Collection: To support diabetic patients, we offer professional and hygienic home sample collection services across Karachi.
• Rapid Turnaround Time: Our streamlined laboratory workflows guarantee that your quarterly diabetes reports are ready within 12 to 24 hours.
• Seamless Digital Access: Patients can easily retrieve, track, and archive their medical reports via our user-friendly website portal and mobile application.
• Extensive Branch Network: With numerous collection centers throughout Karachi and beyond, accessing premium diagnostic services is highly convenient.